<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01104545</url>
  </required_header>
  <id_info>
    <org_study_id>2010_525</org_study_id>
    <secondary_id>MK3614-001</secondary_id>
    <nct_id>NCT01104545</nct_id>
  </id_info>
  <brief_title>A Single Dose Study of MK3614</brief_title>
  <official_title>A Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK3614</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine if MK3614, given as single doses, is safe and well tolerated in
      healthy males and male subjects with mild to moderate hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability of MK3614 given as single doses measured by number of clinical and laboratory adverse experiences</measure>
    <time_frame>14 days after administration of last dose of study drug</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Panel A - Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>.25 mg - 1.25 mg - Pbo - 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel A - Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>.25 mg - 1.25 mg - 5 mg - Pbo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel A - Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>.25 mg - Pbo - 5 mg - 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel A - Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pbo - 1.25 mg - 5 mg - 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B - Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>.5 mg - 2.5 mg - Pbo - 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B - Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>.5 mg - 2.5 mg - 10 mg - Pbo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B - Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>.5 mg - Pbo - 10 mg - 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B - Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pbo - 2.5 mg - 10 mg - 40 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK3614</intervention_name>
    <description>single rising oral dose of MK3614</description>
    <arm_group_label>Panel A - Sequence 1</arm_group_label>
    <arm_group_label>Panel A - Sequence 3</arm_group_label>
    <arm_group_label>Panel A - Sequence 2</arm_group_label>
    <arm_group_label>Panel A - Sequence 4</arm_group_label>
    <arm_group_label>Panel B - Sequence 1</arm_group_label>
    <arm_group_label>Panel B - Sequence 2</arm_group_label>
    <arm_group_label>Panel B - Sequence 3</arm_group_label>
    <arm_group_label>Panel B - Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>single dose oral placebo</description>
    <arm_group_label>Panel A - Sequence 1</arm_group_label>
    <arm_group_label>Panel A - Sequence 2</arm_group_label>
    <arm_group_label>Panel A - Sequence 3</arm_group_label>
    <arm_group_label>Panel A - Sequence 4</arm_group_label>
    <arm_group_label>Panel B - Sequence 1</arm_group_label>
    <arm_group_label>Panel B - Sequence 2</arm_group_label>
    <arm_group_label>Panel B - Sequence 3</arm_group_label>
    <arm_group_label>Panel B - Sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects between 18 to 45 years of age; otherwise healthy subjects between 18
             to 55 years of age newly diagnosed with grade 1 or 2 hypertension

          -  Subject is in good general health

          -  Subject is a nonsmoker

        Exclusion Criteria:

          -  Subject has a history of stroke, seizure or major neurological disease

          -  Subject has functional disability that can interfere with rising from a sitting
             position to a standing position

          -  Subject has a family history of a bleeding or clotting disorder

          -  Subject has a history of cancer

          -  Subject is unable to refrain from or anticipates the use of any prescription or
             non-prescription medication during the study

          -  Subject consumes excessive amounts of alcohol or caffeine Subject has had major
             surgery, donated blood or participated in another investigational study in the past 4
             weeks.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2010</study_first_posted>
  <last_update_submitted>April 13, 2010</last_update_submitted>
  <last_update_submitted_qc>April 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Executive Vice President, Clinical and Quantitative Sciences</name_title>
    <organization>Merck Sharp &amp; Dohme Corp</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

